.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Express Scripts
Accenture
Novartis
Harvard Business School
AstraZeneca
Argus Health
Teva
Queensland Health

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,713,086

« Back to Dashboard

Which drugs does patent 6,713,086 protect, and when does it expire?


Patent 6,713,086 protects DEPAKOTE ER and is included in one NDA. There have been two Paragraph IV challenges on Depakote ER.

Protection for DEPAKOTE ER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in twenty-seven countries.

Summary for Patent: 6,713,086

Title: Controlled release formulation of divalproex sodium
Abstract:A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
Inventor(s): Qiu; Yihong (Gumee, IL), Bollinger; J. Daniel (Libertyville, IL), Cheskin; Howard S. (Glencoe, IL), Dutta; Sandeep (Waukegan, IL), Engh; Kevin R. (Kenosha, IL), Poska; Richard P. (Mundelein, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/215,142
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-002May 31, 2002ABRXYesNo► Subscribe► SubscribeY
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,713,086

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,419,953 Controlled release formulation of divalproex sodium► Subscribe
6,528,091 Controlled release formulation of divalproex sodium► Subscribe
6,720,004 Controlled release formulation of divalproex sodium► Subscribe
6,528,090 Controlled release formulation of divalproex sodium► Subscribe
6,511,678 Controlled release formulation of divalproex sodium► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,713,086

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland356899► Subscribe
Portugal1140034► Subscribe
Portugal1216704► Subscribe
Norway20012986► Subscribe
South Korea20010101295► Subscribe
Japan2003513882► Subscribe
Israel143407► Subscribe
Hungary0105463► Subscribe
Hong Kong1043043► Subscribe
Spain2228762► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
McKinsey
US Department of Justice
UBS
Daiichi Sankyo
Merck
Argus Health
Novartis
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot